Clinical trials: Inflammatory Bowel Disease, Ulcerative Colitis Type
- Condition Inflammatory Bowel Disease, Ulcerative Colitis Type
- Funder type Industry (pharma, biotech, devices)
UC - Ulcerative Colitis, Moderately to Severely Active Ulcerative Colitis
A Phase 2 Study of D-2570 in Subjects With Moderately to Severely Active Ulcerative Colitis
This study is a multicenter, randomized, double-blind, placebo-controlled clinical trial. The target population is patients with moderately to severely active ulcerative colitis. A total of 120 subjects are planned to be included.
- Trial name
- D2570-202 (NCT07035041)
- Testing
- D-2570
- Where
- China
- Volunteers
- 120 people
- Sponsor
- InventisBio Co., Ltd
Ulcerative Colitis in Remission
Comparative Efficacy and Safety Study in Patients With Ulcerative Colitis in Remission Phase
To demonstrate that import Mesalazine (ASACOL®) is non-inferior to the reference drug, marketed Mesalazine, regarding the primary endpoint (rate of non-emergence of bloody stool), in patients with Ulcerative Colitis in remission…
- Trial name
- NCT01257399
- Testing
- Asacol®, Mesalazine
- Where
- China
- Volunteers
- 251 people
- Sponsor
- Tillotts Pharma AG
Ulcerative Colitis (UC)
Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BCD-261 in Subjects With Moderate to Severe Active Ulcerative Colitis
The aim of the study is to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics and immunogenicity of study drug (BCD-261) in comparison with placebo and to characterize the dose-response relationship in patients…
- Trial name
- ULTRAMARINE (NCT07080034)
- Testing
- anti-TL1A monoclonal antibody, low dose, anti-TL1A monoclonal antibody, medium dose, anti-TL1A monoclonal antibody, high dose
- Where
- 20 sites in Russia
- Volunteers
- 198 people
- Sponsor
- Biocad
Colitis, Ulcerative
A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Ulcerative Colitis (UC)
Vedolizumab is a medicine that helps to reduce inflammation and pain in the digestive system. In this study, children and teenagers with moderate to severe ulcerative colitis will be treated with vedolizumab.
- Trial name
- NCT04779307
- Testing
- Vedolizumab
- Where
- 65 sites in United States, Australia and 12 more
- Volunteers
- 121 people
- Sponsor
- Takeda
Ulcerative Colitis
Safety and Pharmacokinetics Study of HE3286 in Patients With Active, Mild-to-Moderate Ulcerative Colitis
The purpose of this pilot, exploratory study is to evaluate the safety, tolerance, pharmacokinetics and potential activity of an investigational agent, HE3286, when administered orally, daily for 28 days to patients with…
- Trial name
- NCT00628433
- Testing
- HE3286
- Where
- 10 sites in United States
- Volunteers
- 27 people
- Sponsor
- Harbor Therapeutics
Ulcerative Colitis, Colitis, Ulcerative
VE202 in Patients With Mild-to-Moderate Ulcerative Colitis
A Phase 2 study to evaluate the safety, efficacy, and microbiota changes of VE202 in patients with mild to moderate ulcerative colitis (UC).
- Trial name
- NCT05370885
- Testing
- VE202, Vancomycin Oral Capsule
- Where
- 49 sites in United States, Australia and 8 more
- Volunteers
- 114 people
- Sponsor
- Vedanta Biosciences, Inc.
Ulcerative Colitis and Crohn's Disease
Entyvio (Vedolizumab) Long Term Safety Study
The purpose of this study is to assess the long-term safety of vedolizumab versus other biologic agents in participants with Ulcerative Colitis (UC) or Crohn's Disease (CD).
- Trial name
- Entyvio PASS (NCT02674308)
- Testing
- Vedolizumab, Other Biologic Agents
- Where
- 287 sites in United States, Austria and 19 more
- Volunteers
- 5,302 people
- Sponsor
- Takeda
Ulcerative Colitis
Efficacy and Safety Study of Apremilast to Treat Active Ulcerative Colitis
The purpose of the study is to evaluate the clinical efficacy, safety and tolerability of apremilast (30 mg twice daily [BID] and 40 mg BID), compared with placebo, in participants with active Ulcerative Colitis (UC).
- Trial name
- UC (NCT02289417)
- Testing
- Apremilast
- Where
- 99 sites in United States, Australia and 12 more
- Volunteers
- 170 people
- Sponsor
- Amgen
Ulcerative Colitis
Study of the Efficacy and Safety of AMT-101 in Subjects With Ulcerative Colitis (LOMBARD)
Randomized, Placebo-controlled, Double-blind, Parallel-group, Multicenter, Phase 2a Study of the Efficacy and Safety of Oral AMT-101 in Subjects with Moderate to Severe Ulcerative Colitis.
- Trial name
- NCT04583358
- Testing
- AMT-101 (oral)
- Where
- 59 sites in United States, Belarus and 12 more
- Volunteers
- 105 people
- Sponsor
- Applied Molecular Transport
Ulcerative Colitis, Crohn's Disease
Vedolizumab IV in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)
The purpose of this study is to evaluate vedolizumab pharmacokinetics (PK), safety and tolerability in pediatric participants with moderately to severely active UC or CD.
- Trial name
- NCT03138655
- Testing
- Vedolizumab
- Where
- 88 sites in United States, Belgium and 9 more
- Volunteers
- 89 people
- Sponsor
- Takeda
Ulcerative Colitis
A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 6 Weeks in Adults With Ulcerative Colitis
The primary objective of this study was to evaluate the effect of GLPG3970 compared to placebo on the signs and symptoms of Ulcerative Colitis (UC) in participants with moderately to severely active UC.
- Trial name
- SEA TURTLE (NCT04577794)
- Testing
- GLPG3970
- Where
- 15 sites in Georgia, Moldova and 2 more
- Volunteers
- 31 people
- Sponsor
- Lakefront Biotherapeutics NV
Ulcerative Colitis (UC)
Hemay005 for the Treatment of Chinese Moderately to Severely Active Ulcerative Colitis
The purpose of this phase III, multicenter, double-blind, placebo-controlled study is to evaluate the efficacy and safety of Hemay005 compared to placebo as induction and maintenance therapy in Chinese participants with…
- Trial name
- NCT07650942
- Testing
- Hemay005 tablet
- Where
- 2 sites in China
- Volunteers
- 360 people
- Sponsor
- Ganzhou Hemay Pharmaceutical Co., Ltd
Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC)
A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
This is a Phase 2, multicenter, platform study in adult participants with IBD (moderately to severely active Crohn's Disease or Ulcerative Colitis).
- Conditions
- Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC), Crohn's Disease
- Trial name
- ASCEND-IBD (NCT07113522)
- Testing
- MT-501, MT-201
- Where
- 66 sites in United States, Canada and 3 more
- Volunteers
- 140 people
- Sponsor
- Mirador Therapeutics, Inc.
Crohn Disease, Colitis, Ulcerative
A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease
The primary objective is to characterize the efficacy TEV-48574 in adult participants with IBD (moderate to severe Ulcerative Colitis (UC) or Crohn's Disease (CD)) as assessed by induction of clinical remission (UC) and…
- Trial name
- RELIEVE UCCD (NCT05499130)
- Testing
- TEV-48574
- Where
- 164 sites in United States, Austria and 17 more
- Volunteers
- 290 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Ulcerative Colitis, Crohn's Disease
A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
Ulcerative Colitis (UC) and Crohn's Disease (CD) are long-term conditions in the gut that can cause diarrhea, swelling (inflammation), bleeding from the anus, and belly pain.
- Trial name
- PANORAMA (NCT06581328)
- Testing
- Vedolizumab IV, Vedolizumab SC
- Where
- 101 sites in United States
- Volunteers
- 200 people
- Sponsor
- Takeda
Ulcerative Colitis, Crohn Disease
Systems Biology of Gastrointestinal and Related Diseases
This is a longitudinal observational study on patients with gastrointestinal and related disease. The study will be conducted for at least 10 years, following each participant over time, as they either go through relapses and…
- Conditions
- Ulcerative Colitis, Crohn Disease, Obesity, Colon Polyp
- Trial name
- NCT05579444
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Viome
Inflammation, Ulcerative Colitis
A Placebo-controlled Trial With rFXIII Administered to Subjects With Mild to Moderate Active Ulcerative Colitis
This trial is conducted in Europe. The aim of the trial is to investigate the effect of recombinant factor XIII (rFXIII) administered to subjects with mild to moderate active ulcerative colitis (UC).
- Trial name
- NCT01706159
- Testing
- catridecacog
- Where
- 7 sites in Bulgaria, Croatia and 5 more
- Volunteers
- 20 people
- Sponsor
- Novo Nordisk A/S
Ulcerative Colitis
Efficacy/Safety of ALTB-268 in Subjects w/Moderately to Severely Active UC Refractory to Biologics
ALTB-268-201 is a Phase 2a, multicenter, single arm, multiple-dose, open-label study evaluating the efficacy and safety of ALTB-268 in subjects with moderately to severely active UC.
- Trial name
- NCT06109441
- Testing
- ALTB-268
- Where
- 24 sites in United States, Puerto Rico
- Volunteers
- 50 people
- Sponsor
- AltruBio Inc.
Ulcerative Colitis
Respiratory-gated Auricular Vagal Afferent Nerve Stimulation (RAVANS) Study in Ulcerative Colitis
Prospective, single-center, sham-controlled, double-blinded 12-week study designed to evaluate the safety and efficacy of the RAVANS device in subjects with Ulcerative Colitis.
- Trial name
- NCT05662059
- Testing
- RAVANS
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Cala Health, Inc.
Fibrostenotic Crohn's Disease
A Study of PALI-2108 in Healthy Volunteers, Patients With Ulcerative Colitis, and Patients With Fibrostenosing Crohn's Disease
This is a Phase 1b, open-label, exploratory study designed to evaluate the pharmacodynamic effects of PALI-2108, a phosphodiesterase-4 (PDE4) inhibitor, in patients with fibrostenotic Crohn's disease (FSCD).
- Trial name
- NCT07428096
- Testing
- PALI-2108
- Where
- Canada
- Volunteers
- 6 people
- Sponsor
- Palisade Bio